535 714

Cited 7 times in

The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition.

DC Field Value Language
dc.contributor.author배수한-
dc.contributor.author이병완-
dc.contributor.author이다현-
dc.date.accessioned2018-11-16T16:42:18Z-
dc.date.available2018-11-16T16:42:18Z-
dc.date.issued2018-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/165242-
dc.description.abstractNon-alcoholic fatty liver disease (NAFLD) is a metabolic disorder closely linked with type II diabetes (T2D). The progression of NAFLD is associated with the induction of lipogenesis through hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway. An increase in lipogenesis induces endoplasmic reticulum (ER) stress and accelerates oxidative liver injury in the pathogenesis of NAFLD. Lobeglitazone, one of thiazolidinediones (TZDs), is used as an antidiabetic drug to lower serum glucose level through an increase in insulin sensitivity. It is known to improve pathological symptoms in animals and humans with NAFLD. However, the underlying molecular mechanism of the protective effects of lobeglitazone against NAFLD has not been elucidated. Here, we show that under the physiological condition of acute lipogenesis, lobeglitazone inhibits hepatic lipid synthesis, the subsequent ER stress, and ω-oxidation of fatty acids by inhibiting the mTORC1 pathway. As a result, lobeglitazone protected mice from lipogenesis-induced oxidative liver injury. Taken together, lobeglitazone might be a suitable drug for the treatment of patients with diabetes and NAFLD.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherFrontiers Research-
dc.relation.isPartOfFRONTIERS IN ENDOCRINOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleThe Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentBioMedical Science Institute (의생명과학부)-
dc.contributor.googleauthorYu Seol Lee-
dc.contributor.googleauthorJeong Su Park-
dc.contributor.googleauthorDa Hyun Lee-
dc.contributor.googleauthorDong-Kyu Lee-
dc.contributor.googleauthorSung Won Kwon-
dc.contributor.googleauthorByung-Wan Lee-
dc.contributor.googleauthorSoo Han Bae-
dc.identifier.doi10.3389/fendo.2018.00539-
dc.contributor.localIdA01798-
dc.contributor.localIdA02796-
dc.relation.journalcodeJ03412-
dc.identifier.eissn1664-2392-
dc.identifier.pmid30298052-
dc.subject.keywordER stress-
dc.subject.keywordNAFLD-
dc.subject.keywordlobeglitazone-
dc.subject.keywordmTORC1-
dc.subject.keywordthiazolidinedione-
dc.contributor.alternativeNameBae, Soo Han-
dc.contributor.alternativeNameLee, Byung Wan-
dc.contributor.affiliatedAuthor배수한-
dc.contributor.affiliatedAuthor이병완-
dc.citation.volume9-
dc.citation.startPage539-
dc.identifier.bibliographicCitationFRONTIERS IN ENDOCRINOLOGY, Vol.9 : 539, 2018-
dc.identifier.rimsid58659-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.